UB392
TargetsCLDN6
IndicationsSolid tumour
ClinicalCN - Pre-PCC
TherapeuticsOncology
ModalitiesADC
Exclusive Summary
- • Lower toxin shedding rate in the blood circulation.
- • CLDN6/9 dual targeting, has the potential to enhance the clinical benefits of double-positive individuals and cover a broader range of indications.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →